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The Need for Better Methods
of Extrapolation
by leo Friedman*
In the fall of 1966 the Food and Drug
Administration established an Advisory Com-
mittee on Protocols for Safety Evaluation.
The first problem to be reviewed was the
requirement for reproduction studies in the
safety evaluation of pesticides and food ad-
ditives, and the adequacy of the current me-
thods involved. Reproduction studies are de-
signed to give information on: (1) effects on
male and female fertility, (2) effects during
gestation on the mother and the fetus, (3)
effects appearing after parturition on the
mother (for example, lactation) and the off-
spring (for example, growth, development,
sexual maturation), and (4) mutagenic ef-
fects, particularly those which might not
appear in the first generation.
The report of panel dealing with this
problem was written in November 1968 and
published later (1). During the time the
panel was considering the problem, a re-
port prepared by the Genetic Study Section
under the chairmanship of Dr. James F.
Crow (2), became available to us (C. C.
Cockerham, personal communication). The
emphasis in this particular report of the
Genetic Study Section was that there is rea-
son to be concerned about chemicals as a mut-
agenic risk equivalent to radiation, possibly
even more serious. The concern, of course,
is with the welfare of future generations as
well as with the health of contemporary pop-
ulations. It is useful to emphasize again that
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methods to detect mutagenic effects that are
useful for the evaluation of mutagenic risks
must deal with the potential for genetic
changes that are transmissible to future gen-
erations. Without this clearly in mind we can
easily become confused regarding the import
of our laboratory findings.
I believe it is of interest to this group
to cite certain portions of the Reproduction
Panel Report (1).
1. "There should be a repository of in-
formation on the mutagenic potential of
chemicals. Such information should include
chemical nature, quantitative information on
mutagenicity, the particular test systems on
which this information is based, and other
biological effects including carcinogenesis."
2. "The task of demonstrating that a chem-
ical constitutes no genetic hazard is some-
what different and inherently much more
difficult than carrying out and evaluating
other toxicity tests including reproduction
tests. The 'permissible level' takes on new
meaning when multiplied over future genera-
tions. MIutagens often act at very low concen-
tration. Definitive tests of their effects in
mammals are tedious and expensive. Gener-
ally, the more sensitive and feasible the
screening test is for chemical mutagens, the
further the test organism is removed from
man. Little information is available about the
applicability of non-mammalian assay sys-
tems to mammals."
3. "Because there is already evidence that
some chemicals are mutagenic in some test
systems, all new chemicals to which human
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in some way for mutagenic effects. The most
definitive tests (specific locus tests and back-
cross or genetic load tests) for chemical mut-
agenesis in mammals are clearly impractical
because they require approximately one-half
million animals, or more, depending on test
circumstances, to detect a doubling of the
mutation rate. Feasible is the dominant lethal
test in mice and/or rats as outlined by Bate-
man" (3).
"It is likely that occasionally a chemical,
which does not constitute a hazard to human
health under the actual conditions of use,
might be shown to be mutagenic by simpler
test systems. For example, a chemical when
added to the culture media of microorgan-
isms might produce a detectable increase in
mutation frequency, but be innocuous to man
because of degradation in the gut, detoxifica-
tion, or other reasons. The same comments
are appropriate for cytological tests with
cultivated cells. Further tests would be in
order for a chemical which is suspect as
might be indicated by positive results of sim-
ple screening tests or by existing informa-
tion such as known mutagenicity of related
compounds already recorded in the registry."
"Test procedures in simple systems are
also open to the criticism that negative re-
sults do not prove that a chemical will not
be mutagenic to man. Among possible rea-
sons for this are the high degree of specificity
of the tests and production of active metabol-
ites. Consequently, the proper evaluation of
the non-mutagenicity of chemicals may be ac-
complished best through a series of tests,
first being direct tests on microorganisms
for specific effects and on cultivated mam-
malian cells for chromosomal aberrations. In
the event that results of direct tests are nega-
tive (which still leaves the possibility of
mutagenic metabolites being formed in the
animal) or that the potential value of the
substance warrants the effort, tests in mam-
malian systems should be undertaken.
4. "The simple bacterial tests are for back
mutations, and only if mutagens produce both
forward and backward mutations with
roughly equal frequencies are these tests ade-
ouate. Since results of different systems do
not always agree, at least two bacterial sys-
tems should be used to test for specific ef-
fects."
"Of the tests currently available (Novem-
ber 1968) using mammalian systems, three
types are suggested: (1) dominant lethal
tests in mice (possibly rats); (2) cytological
tests of cells removed from treated animals,
and (3) mammalian host-mediated microbial
assays. If results of a dominant lethal test
and of one other test in a mammalian system
as well as results of the 'direct tests' are neg-
ative, the chemical may be judged to be non-
mutagenic. When the results of 'direct tests'
are positive, additional data comparing the
metabolism of the compound in the animals
used in the mammalian tests to its metab-
olism in man should be available before the
hazard of mutagenesis in humans can be
evaluated."
Since this report was written there has
been very rapid development in mutagenesis
assay systems and their application to a
great variety of substances. The specific
concern over the contributions of environ-
mental agents to the problem of genetic dis-
ease was thus widely recognized and we are
now at an important crossroad as we recog-
nize the need to better equip ourselves for the
task of extrapolating from the results of our
laboratory studies to the potential risk to hu-
man populations.
The Mrak Commission Report (4) con-
tained a chapter on mutagenicity of pesti-
cides. The various methods for mutagenicity
testing were fully reviewed by the Mutage-
nicity Panel and a recommended program for
mutagenicity testing was set forth. The rec-
ommended protocol included the test of each
compound in three mammalian systems, the
dominant-lethal, host-mediated, and in vivo
cytogenetic, by appropriate methods of ad-
ministration reflecting human exposure and
also parenterally and at high dose levels such
as maximal tolerated doses. Also, each com-
pound should be tested in ancillary microbial
systems, preferably those detecting both sin-
gle nucleotide changes and effects involving
more than one gene.
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would be such that doubling of the control
level of mutation would be statistically sig-
nificent at the 5%7 level. If one or more of the
three mammalian tests shows a significant
effect, the test is regarded as positive. A
pesticide is regarded as negative if none
of the tests is significantly different from
its control. If only the microbial test is posi-
tive, more detailed mammalian tests are in-
dicated.
These recommendations and others not
quoted indicated, on the one hand, a degree
of confidence in the precision and interpret-
ability of results from these methods, and on
the other, a degree of uncertainty which ac-
curately reflected the lack of experience of
all concerned with the problems of methodol-
ogy and with the interpretation of results
from mutagenesis testing.
There seems to be agreement among two
separate panels that the dominant lethal tests
on rodents, somatic and/or germinal cell cyto-
genetics and the newly developed host-medi-
ated assay were the methods of choice in any
program of safety evaluation that was to in-
clude specific attention to the problem of
mutagenesis. Therefore, when the Food and
Drug Administration, in response to the dir-
ective of the White House Conference on
Nutrition, undertook to re-examine the sub-
stances used in food that had been listed as
generally recognized as safe-(GRAS), it was
logical that the question of mutagenesis
should be seriously considered. All of these
substances had had a considerable history of
human use but had not been studied as ex-
tensively as any new food additive. There
were gaps in knowledge, therefore, especially
in regard to newer questions such as mut-
agenicity and teratogenicity, and these could
be dealt with only by application of ap-
propriate laboratory methods.
Therefore, about a year or two ago, the
FDA undertook mutagenicity testing of
GRAS compounds on a relatively large scale.
From the beginning it was recognized that
not only were substances being tested but
that new laboratories which had contracted
to undertake the task were acquiring experi-
ence in a new area, and that the test systems
themselves were being scrutinized.
The Mrak Commission Panel had stated
that "the testing procedures recommended
above must be constantly updated and im-
proved to reflect new techniques and new
data." This large-scale undertaking by FDA
would provide new experience and data,-and
would inevitably have an impact'on our-un-
derstanding of the methods used and our con-
fidence in results and our ability to interpret
these results in terms of the risk to human
populations.
I believe we can all agree that essential
to any procedure used for safety evaluation
is an acceptable degree of reproducibility.
Equally important is that the test procedure
relate to a health-hazard to 'which man 'is--
known to be susceptible. For instance, we-'
know that people are poisone&c-in-the same
way that our laboratory animals -are when-
we determine lethal doses. We know that man
is subject to cardiovas'cular effects, carcino-
genicity, and teratogenicity --and other
chronic and acute health -problems', so that
studies of these specific problems -in animal
models are easily translatable,-at least con-
ceptually.
The situation with mutagenicity testing
has been very- different than that where
biological endpoints have been traditionally
used. Here the endpoints are not always
clearly related to the structural or functional
effects which are of known concern to man.
Indeed, the relationships seem sometimes on
tangential and based on purely mechanistic
consideration. It is assumed, for example,
that if the compound is found to induce a
sex-linked recessive lethal mutation, it would
also induce an increased frequency of ga-
lactosemia, phenylketonuria, or any number
of other recessive conditions in which the
specific gene product has been rendered func-
tionless by mut-ation.- This concept is sup-
ported better by theory than by observation
or direct demonstration, but it points out an
essential fact. A great deal more is known
about mutagenesis in terms of mechanism
than is true for- most areas of toxicology.
In mutagenesis, the chemical nature of the
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mechanisms are at least as well understood
as any event in biology. Thus, mutagenesis
may occupy a special place in toxicology
wherein test system endpoints and human
health effects may possibly not be as strin-
gently related as appears necessary in other
areas.
On the other hand, we must be certain
that our experimental model is relevant to
the problem, that we are comparing apples
to apples, and not to oranges. We must, there-
fore, identify the genetic events which are
of concern to man and focus our efforts on
these events by selecting test systems which
are suitable for such purposes.
Presumably, we know a good deal about
the types of mutations which are of concern
in man from the specific protein products
generated by mutation. For instance, it is
known from studies of the globin molecule
that gene mutations in man include point
mutations. These have either been shown or
presumed to include base substitution or
base addition or deletion. Small chromosomal
deletions either of a terminal or inter-
stitial nature are also known to be responsi-
ble for gene mutations in mammals and as
such deserve our concern. While there are a
number of systems capable of measuring any
one of these effects, we need to select the
one or ones most closely relevant to man.
We further need to be mindful of the need
to assess the effects and consequences of
pharmacokinetic factors upon the compound
in question. Ultimately, we must derive quan-
titative information in sufficiently precise
terms to define mutagenic risk.
In addition to gene mutations, it is ob-
vious that man is subject to a significant
cytogenetic disease burden as exemplified
by Down's, Klinefelter's and Turner's syn-
dromes and a variety of other conditions
known to be of cytogenetic origin. These
heritable conditions are predicated on cer-
tain types of cytogenetic anomalies but it is
not known whether these anomalies are in-
duced by the same chemicals which are cap-
able of inducing gene mutations and if so,
whether such alterations can accumulate
within the germinal stem line and be trans-
mitted to future generations. Such informa-
tion is necessary if we are to achieve proper
understanding of the problem leading to-
wards effective safety or risk evaluations. In-
deed it is appropriate to cite Brent, who
emphasized: Do not adopt a testing proto-
col whose results are uninterpretable for
human situation (5). Clearly, we must ad-
dress ourselves to this central question and
objectively examine and evaluate all mut-
agenicity tests in terms of whether they
can or will provide the kind of information
which is applicable to human safety evalua-
tion. This is the important charge for this
Workshop.
Specifically, we must ask the following
question of any current or proposed mut-
agenicity test system: (1) Are the events
measured heritable and to what extent would
they accumulate either in germinal stem
cells or within the human population? (2)
Does the assay properly account for all es-
sential pharmacokinetic factors relevant to
human exposures? (3) Are the genetic events
measured of concern to human health? (4)
Is the assay applicable to the types of ex-
posures which are of greatest presumed haz-
ard to man, i.e., what is the probability of
a given dose reaching a given number of
people? (5) To what extent can the assay
yield quantitative information useful in rank-
ing chemical mutagens in terms of mut-
agenic potency?
If this Workshop Study Group agrees that
these questions are essential ones to ask, the
suggestion is made that they serve as a basis
for the panel discussions.
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